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Introduction
Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin Amer-
ica, where it is endemic in all countries. With an overall estimate of 65 million people at risk
of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas
disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic
countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Swit-
zerland [9,10], and France [11] have experienced the occurrence of Trypanosoma cruzi–in-
fected and Chagas disease cases; the majority of these cases are among immigrants coming
from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs),
Chagas disease affects mostly poor populations with limited access to health services. Vector
transmission is associated with poor housing in periurban and rural areas. After infection, the
disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%–30% of
the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining in-
fected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactiva-
tion of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS,
organ transplants, or immunosuppressive therapy [14].
Following resolutions from the Pan American Health Organization (PAHO) andWorld
Health Organization (WHO) on the prevention, care, and control of Chagas disease, several
countries in the Americas have strengthened control activities and achieved significant prog-
ress towards this goal. Yet, the disease remains prevalent among marginalized populations in
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the continent; many patients remain undiagnosed and untreated, making Chagas disease the
NTD with the highest burden in Latin America countries. In addition, infected and diseased in-
dividuals are increasingly diagnosed in different parts of the world [15].
Case management and treatment are essential strategies to eliminate Chagas disease as a
public health problem. However, ensuring diagnosis and access to treatment for millions of in-
fected people continues to be a challenge. Timely diagnosis and trypanocidal treatment are
known to reduce the likelihood of disease progression and to prevent congenital transmission.
Indeed, Chagas disease has been categorized as “the most neglected of the neglected diseases,”
with lingering research and development gaps related to its treatment and diagnosis [16].
During the acute phase, diagnosis relies primarily on direct parasitological tests and second-
arily on serological testing. Alternatively, during the chronic phase, diagnosis relies primarily
on serological tests and secondarily on molecular tests, which are not readily available in pri-
mary health centers outside urban areas. Currently available diagnostic methods and medi-
cines, however, are considered suboptimal for adequate control and treatment programs,
reflecting the lackluster investment devoted to this disease [17]. At this time, the two available
treatments, nifurtimox and benznidazole, are largely considered to be effective in the acute and
early chronic infection and in preventing congenital transmission in children born to infected
and treated mothers [18]. While there is a growing body of information to support the use of
these medicines in the later stages of the disease, the effectiveness of these drugs outside the
acute phase and the safety profile of these treatments need to be further established. Treatment
is contraindicated during pregnancy, severe renal or hepatic insufficiency, and severe granulo-
citopenia and aplastic anemia in immunosuppressed patients, and thus, newer medicines with
better risk-benefit profiles are necessary [17,19]. For diagnosis, there is a lack of effective tools
for large-scale screening, point-of-care diagnosis, and monitoring patient’s response to antipar-
asitic treatment. In the case of asymptomatic acute infections, active search is preferred, involv-
ing direct parasitological methods and serology (immunoglobulin M [IgM] antibody anti-T.
cruzi) for contacts or suspects. Serological tests are not considered to be reliable in endemic
areas for diagnosis of acute asymptomatic infection because of the absence of good standard-
ized commercial kits. Standard diagnostic protocols are hard to implement outside of large
urban centers where one can anticipate a large number of infected individuals.
The complexity of the equipment that is required, the need for highly trained personnel,
and the need for the patient to come to the health center more than once are among some of
the most pressing constraints. Moreover, serodiagnosis in infants born to seropositive mothers
has low positive predictive value due to the passive transfer of maternal anti-T. cruzi IgGs. At
the same time, a small but sizeable number of infected newborns may be seronegative. Thus, it
is recommended to conduct parasite search in this population using microhematocrit, hemo-
culture (HC), and PCR; none of these tests are easily performed outside laboratories perform-
ing tests of moderate and high complexity. Hence, developing new diagnostic tools that are
easy to use and adapted to the needs of affected populations and to the reality of health systems
based on primary health care will greatly improve the ability to control Chagas disease in the
Americas [16,20].
A first and critical step to address the research and development gap is to establish a consen-
sus on the desirable product profiles in different conditions of use. To foster and inform the de-
velopment of these much needed tools, PAHO, in collaboration with the Drugs for Neglected
Diseases initiative (DNDi), Médecins sans Frontières (MSF), and the Special Programme for
Research and Training in Tropical Diseases (TDR), convened a multidisciplinary group of ex-
perts in Rio de Janeiro, Brazil (April 2010), to review the evidence and initiate discussions. The
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meeting established the basis for the development of target product profiles (TPPs), which are
reported in this paper.
Target Product Profile Consensus
The working group proposed TPPs for three different scenarios:
1. point-of-care diagnosis for patients in the acute phase (associated with congenital, vector,
oral, transplant, or transfusion transmission and infection reactivation) (Table 1);
2. point-of-care diagnosis for asymptomatic or symptomatic patients in the chronic phase
(Table 2); and
3. assessment of response to antiparasitic treatment in the chronic phase (Table 3).
The group defined the following critical attributes for the different diagnostics methods ac-
cording to the three specific clinical scenarios:
1. current need: as it relates to individual care, population-based programs, and situation of use;
2. medical conduct: why and how the diagnostic tool will be applied;
3. sampling: biological material, volume, preservation, and transportation process;
4. infrastructure needed: equipment, shipping procedures, and temperature control;
5. number of samples recommended per test and fractionation;
6. technical skills to perform the test;
7. testing site and turnaround time: time from obtaining samples to produce results;
8. test reading: as qualitative or quantitative;
9. taxonomic diagnosis: the capacity to differentiate parasite strains;
10. sensitivity: the ability to correctly identify all positive cases expressed in percentage; and
11. specificity: the ability to correctly identify all negative cases expressed in percentage (and
the risk of cross-diagnosis of other prevalent diseases)
Establishing a TPP for the diagnostics and treatment monitoring of T. cruzi infection is an
important step to guide research and development efforts.
In this paper, the TPPs are proposed according to the demands and needs of different popu-
lation groups and today’s diagnostics and treatment-monitoring challenges. These TPPs repre-
sent ideal features of a test adapted to the usual medical conditions in endemic countries. The
proposed profiles take into consideration the ease of obtaining samples and the difficulties of
transportation and processing them at the point of care, as well as the required infrastructure
and the skills needed for performing the test. Irrespective of its specific characteristics and po-
tential uses, the following attributes should be common to any ideal Chagas diagnostic test for
public health use:
• Low cost, sustainable production and supply requirements, and based on simple manufactur-
ing and distribution methods
• The diagnostic kits should contain all necessary materials for obtaining the sample and per-
forming the test
• All reagents and other kit materials should be stable in prevalent climatic conditions
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• Ease of disposal in accordance with standards of biosecurity
• Acceptability by the health system and target population
The consensus of the group is summarized in Tables 1–3.
Table 1. TPP for point-of-care diagnosis for patients in the acute phase of Chagas disease.
Needs for
Diagnosis
Medical
Conduct
Samples
and
Sampling
Infrastructure Technical
Skills
Testing Site,
Turnaround
Time
Reading Taxonomic
Diagnosis
Sensitivity Speciﬁcity
Congenital
transmission
Serodiagnosis
of pregnant
women and
women
admitted at
delivery living
or born in
endemic
countries
(knowing that
>70% have no
signs or
symptoms)
Samples
processed
individually.
(i) Maximum.
2 ml of cord
or peripheral
blood
obtained
speciﬁcally
for diagnostic
test; (ii)
Blood
sample
collected for
routine
screening for
infectious or
metabolic
diseases; (iii)
Ideal: urine
sample
(i) Ideal:
processing at
point of care;
(ii) Less
desirable:
samples
processed in a
reference
laboratory
transported
without cold
chain
Good
laboratory
practices
(GLP)–
trained
technical
staff with
quality
certiﬁcation.
Screening
conducted by
staff who
assisted the
childbirth
Primary
health centre
(PHC),
hospital or
delivery
institution.
Ideal timing:
<1 h, up to a
maximum of
12 h from
sampling
Qualitative Single
universal
test should
detect all
circulating
strains
>95% 100%. Ideal:
integrated into
routine health
care screening
(e.g., metabolic
screening)
Vector and
oral
transmission
(i) Differential
diagnosis for at
risk population
with febrile
syndrome; (ii)
Active search in
cases of
possible
exposure
(contacts)
Samples
processed
individually.
(i) 2–5 mL
blood or
serum; (ii)
Ideal: urine,
saliva
sample
(i) Ideal:
processing at
point of care;
(ii) Less
desirable:
samples
processed in a
reference lab
and
transported
without cold
chain
GLP-trained
technical
staff with
quality
certiﬁcation
PHC and/or
community-
based
diagnosis
facility. Ideal
timing: <1 h
from sampling
Qualitative/
quantitative
Single
universal
test should
detect all
circulating
strains
>95% 100%. Ideal:
integrated into
routine health
care screening
(e.g., metabolic
screening).
Should
differentiate T.
cruzi from T.
rangeli
Reactivation
of infection
associated
with immune
suppression
in organ
transplants.
Blood
transfusion
transmission
Active
surveillance
Samples
processed
individually.
Blood,
cerebral
spinal ﬂuid,
tissue from
chagoma
(i) Ideal:
processing at
point-of-care;
(ii) Less
desirable:
samples
processed in a
reference
laboratory and
transported
without cold
chain
GLP-trained
technical
staff with
quality
certiﬁcation
Reference
medical
facility, blood
banks, and
hospital. Ideal
timing: <1 h
from sampling
Qualitative/
quantitative
Single
universal
test should
detect all
circulating
strains
>95% 100%. Ideal:
integrated into
routine
screening.
Should
differentiate
between T.
cruzi and T.
rangeli. In the
case of
diagnosis in
central nervous
system
manifestations
of HIV/AIDS, it
should
differentiate T.
cruzi from other
opportunistic
infections, such
as
toxoplasmosis.
doi:10.1371/journal.pntd.0003697.t001
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Discussion
Access to appropriate diagnostic tools is critical for individual care and public health control of
Chagas disease. A series of publications have reviewed the current challenges related to diagno-
sis and monitoring of treatment response in patients affected with this disease [16,17,19,20–
22]. Many have pointed to the need for an effective and affordable point-of-care test that can
be used in endemic areas and administered by low-skilled health workers. This would greatly
improve the detection of Chagas disease infections and facilitate appropriate treatment for af-
fected populations, thus reducing the burden to individuals and to the health care system.
Detection of circulating parasites through a series of direct or indirect assays is the approach
of choice for diagnostics during the acute phase of Chagas disease. In the acute phase, antipara-
sitic treatment can eliminate parasites and prevent chronic phase complications. A large pro-
portion of patients remain undiagnosed at this stage, however, because of subclinical
Table 2. TPP for point-of-care diagnosis for patients in chronic phase of Chagas disease.
Needs for
Diagnosis
Medical
Conduct
Samples
and
Sampling
Infrastructure Technical
Skills
Testing Site,
Turnaround
Time
Reading Taxonomic
Diagnosis
Sensitivity Speciﬁcity
Asymptomatic
infected
patients,
referred
symptomatic
individuals,
and positive
blood donors
Active
search in
endemic/
nonendemic
and remote
areas;
prenatal
screening
Samples
processed
individually.
Ideal: saliva/
urine;
Alternative:
whole blood,
plasma or
serum
Point of care,
including
community-
based facility
external to
health center
(no
transportation
required)
Adequately
trained
technical
staff or
community
works with
minimum
quality
certiﬁcation
standards
PHC and
community
setting
(home,
school, or
community
center); Ideal
timing: <1 h
from
sampling
Qualitative Single
universal
test should
detect all
circulating
strains
Equal to or
greater
than
standard
serological
tests
100%. No
cross-
reaction with
other
parasites
(e.g.,
Leishmania,
T. rangeli)
doi:10.1371/journal.pntd.0003697.t002
Table 3. Assessment of response to anti-parasitic treatment in the chronic phase.
Needs for
Diagnosis
Medical
conduct
Samples
and
Sampling
Infrastructure Technical
Skills
Test Site Reading Taxonomic
Diagnosis
Sensitivity Speciﬁcity
Assess
antiparasitic
therapeutic
response
(based on
persistent
negativization
of parasitemia
or reduced
parasitic load
evaluation
though
molecular
biology
methods)1
Direct or
indirect
demonstration
of the presence
of the parasite
in blood or
tissue: (i)
Before, during,
and after
treatment (end
point >12
months); ii)
Therapeutic
failure (through
the presence of
the parasite or
parasitic DNA/
antigens in
blood)
2–3
samples
(before and
after
treatment),
Ideal: blood
(maximum
of 5 mL
[adults] and
2 mL
[children]);
Ideal: urine
Reference center,
PHC and second
level of care.
Ideally: no cold
chain; Acceptable:
minimum cold chain
(2°C–8°C);
Unacceptable:
conservation < 0°C
(freezer)
GLP-
trained
technical
staff with-
quality
certiﬁcation
Any health
facility
accessible
and
convenient
for the
patient;
Maximum
time for
result: 1
week
Quantitative/
qualitative
Ideal:
taxonomic
diagnosis (in
the case of
therapeutic
failure);
Acceptable:
detects all
circulating
strains, but no
taxonomic
diagnosis
>95% 100%
1There is no consensus on the deﬁnition of cure, but experts agree that the persistent negativization of parasitemia is the most appropriate marker [23].
doi:10.1371/journal.pntd.0003697.t003
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presentation of infection and limited access of the affected populations to the health system.
Moreover, diagnosis of congenital Chagas disease at the time of birth is considered ideal for
timely and effective treatment, particularly in rural areas, since it is difficult for the mothers to
take their children for confirmation of diagnosis at 10 months of age. However, there is some
evidence showing that parasitic loads may increase during the first month of life and sensitivity
of parasitological methods might be better at this period [23]; thus, more studies to assess cost-
benefit of this issue are still needed.
In addition, new tools are needed for situations such as oral transmission outbreaks. These
facts underline the importance of new diagnostic methods that can inform medical and public
health decision-making in endemic countries. Indirect serological methods are currently used
for diagnosis during the chronic or silent stage of the disease. A negative seroconversion has
been used to assess treatment response, but it may involve a long follow-up period, in particu-
lar for chronically infected patients, which is impractical for public health interventions. There
is a renewed interest in measuring treatment response to antiparasitic drugs during the chronic
phase. While the treatment goal for infectious diseases is or should be pathogen elimination,
there are other equally important therapeutic outcomes to be considered [24]. For some infec-
tions, such as AIDS, control and reduction of the pathogen burden are well-recognized strate-
gies for converting a fatal disease into a chronically controlled disease, with the administration
of appropriate treatments. Recent clinical trials may provide definitive evidence that patients
with chronic phase Chagas disease can also benefit from treatment with antiparasitic medicines
[21,24]. Current clinical trials during the indeterminate phase or in chronic cardiac Chagas dis-
ease patients are based on quantitative PCR (qPCR) methods to monitor the levels of circulat-
ing parasites and to detect therapeutic response. Although molecular based techniques are
proven useful in a clinical trial setting [25], it is hard to envision their use, as they stand today,
in the follow-up of extensive populations in the field. A necessary next step is the development
of commercial kits based on recently standardized methods such as real-time PCR [25,26].
Other nucleic acid amplification methods such as loop-mediated isothermal amplification are
currently under standardization [27]. However, these kits might have a more substantial im-
pact on case management in more developed countries. Studies are under way to assess the
negative predictive value of a PCR test to assess sterile cure (Isabela Ribeiro, personal commu-
nication). A recent publication [23] shows that there are several candidate markers, which to-
gether may fulfill acceptable criteria to indicate the efficacy of trypanocidal treatment.
Data from ongoing studies are considered essential to improve assessment of existing mark-
ers and to identify those for early follow-up of treated patients [23]. Thus, developing a more
straightforward technique to directly or indirectly monitor parasitemia in chronic patients that
is easier to standardize for wider use in clinical settings is necessary.
Innovative and promising strategies are currently being tested that may contribute to the de-
velopment of new diagnostic tools for Chagas disease and that comply with several of the crite-
ria included in the proposed TPP. In particular, the tests foreseen to be used at the primary
health centre (PHC) or community level (as noted in column 6 of Tables 1 and 2) should com-
ply with the ASSURED criteria [22]: (1) affordable by those at risk of infection; (2) sensitive
(few false negatives); (3) specific (few false positives); (4) user friendly (simple to perform and
requiring minimal training); (5) rapid (to enable treatment at first visit) and robust (does not
require refrigerated storage); (6) equipment-free; and (7) delivered to those who need it. For
other settings, more complex technologies such as enzyme-linked immunosorbent assay
(ELISA) and PCR might be acceptable. Molecular methods applied to dried blood on filter
paper, which has been carried out for triatomine samples [28,29], could enhance detection ac-
curacy in acute and congenital Chagas disease cases. Moreover, serological methods based on
low-volume samples are currently under standardization and validation [30]. Recently, a
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nanoparticle-based assay using urine as the clinical sample has been developed for diagnosis of
congenital Chagas disease [31].
Novel nucleic acid amplification approaches such as loop-mediated isothermal amplifica-
tion, which are currently undergoing standardization and validation for other trypanosomatide
infections, should be explored in Chagas disease diagnosis [32,33]. While flow cytometry has
been shown to be a good platform, with high sensitivity and specificity for Chagas disease diag-
nosis and post-therapeutic cure monitoring [34,35], the use of flow cytometry-based devices to
develop "point-of-care" TTPs does not seem to be a feasible approach, mainly considering the
complexity and the nonportable nature of these devices.
The elimination of Chagas disease in the Americas requires long-term commitments and
multidimensional strategies. Development of more appropriate diagnostic tools and treatment
options can certainly accelerate and improve the chances of achieving this goal.
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